Date post: | 13-Sep-2014 |
Category: |
Business |
View: | 787 times |
Download: | 1 times |
© 2010 IBM Corporation
Let’s Build A Smarter Planet: What will it mean for Life Sciences?
George Mattathil -
5/17/2011
© 2010 IBM Corporation
The reality of living in a globally integrated world is upon us.
Safety, quality, efficacy of products is challenged more than ever before
Outdated and inefficient (drug) research and development (R&D) has contributed
to expiring patents, dry pipelines and cost
Generic alternatives abound as pricing pressures increase
Globalization efforts and the new economic environment have
constrained resources
The world is connected: economically, socially and technically.
© 2010 IBM Corporation
The need for progress is clear.
Dollars invested in US pharma
and biotech R&D in 2008. Only 4
truly innovative products were
delivered in the same period.2
65.2 billion 50% of patients drop out of their
treatment within the first
year.20% of prescriptions go
unfilled in hard economic times
and 30% of prescriptions are
not refilled.1
90% of drugs work in only
30-50% of people3
74 billion Dollars US lost due to
a 10% counterfeit
drug supply4
1 ―ECONOMIC CRISIS : Pharma Sales Will Drop As Patients Cut Back on Prescriptions‖
2 R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges, March 10, 2009
3 ―Demolished - the myth that allows drugs giants to sell more‖. , The Independent, Dec. 8, 2003.
4 ―Partnership for Safe Medicines Arms Public Against Counterfeit Drugs‖ Dec. 2, 2008 and IBM analysis
© 2010 IBM Corporation
More innovative discovery & development
Better compliance with treatment
Improved patient insights Reduced risk from counterfeits
The opportunity for progress is clear.
Smarter Life Sciences:
Metabasis therapeutics, Inc.
A biopharmaceutical company in the U.S.
speeds time to market for metabolic- and liver-
disease therapies
Smarter Life Sciences:
Merit Foundation
A Netherlands based non-commercial, international
medical organization accesses thousands of
anonymous patient records and monitors patients’
progress and benchmark responses to treatment
against information about others
Smarter Life Sciences:
Ecole Polytechnique Federale de Lausanne
A major Swiss research institute harnesses the
power of supercomputers to model the human brain,
speeding the search for causes and cures of
neurological and psychiatric diseases with the ability
to run simulations in close to real time
Smarter Life Sciences:
GSMS, Inc.
A small U.S. wholesale pharmaceuticals distributor,
contract manufacturer and packaging company
deploys a pharmaceutical track and trace solution
ahead of the competition The demand for change is strong
The 2008 Global CEO Study: ―The Enterprise of the Future‖
© 2010 IBM Corporation
The demand for change is strong.
Gap between envisioned
change and past success
at managing it.
8 in 10 Life Sciences leaders
anticipate substantial
change ahead.
22%
Change Needed
LIFE SCIENCES CEO’S GLOBAL CEO’S
© 2010 IBM Corporation
For life sciences companies, this means leading in the face of global challenges brought on by three key drivers while overcoming two key inhibitors.
COST AND REVENUE PRESSURES
GROWING RAPIDLY
Restructured business models to
streamline overall operations including
strategic outsourcing, partnering and
turning to emerging markets
REGULATORY, POLITICAL AND SOCIETAL
PRESSURES INTENSIFYING
Legislation is forcing investments in
supply chain traceability and promotional
spending analysis
BETTER UNDERSTANDING OF THE
FUNDAMENTALS OF THE DISEASE
Predictability of a treatment’s efficacy and
safety will drive improved outcomes
PRODUCT MODELS MOVE TO BIOLOGICS
Drugs targeted at a defined population
as well as disease-modifying and preventative
in nature
DISRUPTIVE SCIENCE AND
TECHNOLOGY EMERGING
Increased use of medical imaging and
biomarkers in the move to targeted treatments
and personalized medicine
DRIVERS INHIBITORS
© 2010 IBM Corporation
People and the
organization
Technology
Processes
A smarter system forges partnerships in order to deliver treatment solutions which are targeted at the individual patient.
Enhanced
communication with
end consumer
Compliance
Patient persistence
Consumer insights
Collaboration with
Other life sciences
companies
Biotech
Medical device
and diagnostic
manufacturers
Contract
organizations
Academic centers
Hospitals / clinics
Patients
Smarter life sciences
organization
Network of smart partners
Patient / consumer insights
Smarter Discovery
& Development
Smarter
Supply
Chain
Smarter
Sales &
Marketing
© 2010 IBM Corporation
It’s a new world—and life sciences organizations are key players in an economy that demands increased value, safer solutions, better outcomes, sustainability and accountability.
ENGAGE
Enable life sciences to take an active
role in empower a healthier society and
patients by collaborating to improve
breakthrough therapies.
INNOVATE
Develop new business models to
compete more effectively. Fuel
innovation in R&D and drive
greater discovery productivity.
OPERATE EFFECTIVELY
Align and optimize processes to
support patient centered healthcare
delivery and patient safety to drive
better outcomes and an enhanced
experience. LIFE
SCIENCES
© 2010 IBM Corporation
An opportunity for life science organizations
to think and act in new ways.
Innovate Operate Effectively Engage
+ + =
© 2010 IBM Corporation
Smart life sciences: Innovate.
SMART IS
Improving the efficiency of drug discovery
and development through to reformulation
of existing drug products to extend
product life cycle.
SMART IS
Fueling clinical innovation with much
more processing power while
decreasing operating costs.
SMART IS
Integrating all relevant data, reproducing
the control principles of a biological
system and simulating how it
will respond.
SMART IS
Reducing attrition rates and costs
during discovery by use of high
performance computing.
© 2010 IBM Corporation
Smart life sciences: Operate Effectively.
SMART IS
Automating baseline activities in the
supply chain increases responsiveness to
free up time for employees to manage
critical exceptions and focus on higher
value activities.
SMART IS
Automatically analyzing and correlating
information from multiple sources to
identify areas of risk and regulatory
compliance exposures.
SMART IS
Enabling research beyond the current
―trial, file, and archive‖ data usage model
through clinical & safety data accessible
across studies.
SMART IS
Combating risk by building
intelligence into both products
and packaging.
© 2010 IBM Corporation
Smart life sciences: Engage.
SMART IS
Identifying actions to stem the impact
of chronic diseases like diabetes, heart
disease or stroke by modeling
disease progression.
SMART IS
Driving more innovation and short term
revenues through collaboration.
SMART IS
Monitoring impending disasters and
proactively responding so supply of
targeted treatment is available immediately.
SMART IS
Building in interconnectivity across a
network to provide a hands-on view of
the entire supply chain for all parties.
© 2010 IBM Corporation
Smart life sciences:
Ecole Polytechnique Federale de Lausanne (EPFL):
Embarked on Project Blue Brain, a joint research venture
with IBM to create a model of the fundamental building
blocks of the human brain, unprecedented in its scope –
ultimately generating functional models for 10,000
morphologically complex neurons.
Merit Foundation: developed METEOR – Measurement of
Efficacy of Treatment in the Era of Outcome in
Rheumatology – an Internet-based solution that will
revolutionize and improve patient treatment. Clinicians now
have access to thousands of anonymous patient records,
covering several countries and many hospitals; they can
learn from one another on the best treatment for patients.
Innovate.
Innovate.Engage.
Engage.
National Genographic: created a DNA analysis repository that lets researchers and scientists analyze gathered genetic
data and identify patterns among the samples. Private citizens can also contribute samples to the DNA repository, hosted in
an IBM DB2® data server, and view personalized ancestral migration profiles on the organization’s Web site. This has
Establishes one of the largest centralized collections of genetic information, increasing collaboration among scientists
and researchers.
© 2010 IBM Corporation
Golden State Medical Supply, Inc. (GSMS):
Implemented the Pharma Track & Trace Solution using
two-dimensional barcodes, radio frequency
identification (RFID) and other sensors to track
product movements. Puts GSMS in an advantageous
competitive position by making it one of the first
distributors to comply with the new regulations.
Operate Effectively.
Metabasis Therapeutics: Highly-accurate, first-of-a-
kind simulation software significantly lowers drug
discovery time and costs by eliminating 80% of the
compounds to be synthesized and tested in the lab.1
Fujita Pharmaceutical LTD, Co. : Improved its total
project management capabilities. The new solution
helps the company minimize out-of-stock instances
by consistently managing sales, production,
purchases of raw materials and accounting through a
single system.
Bilcare Limited: Developed a Track-and-Trace
Solution framework to seamlessly integrated into any
supply chain system, providing real-time product
authentication. The technology helps detect
counterfeit goods, potentially saving millions of lives
© 2010 IBM Corporation
Smart life sciences: IBM Research Projects
Automatically analyzing and correlating
information from multiple sources to identify
areas of risk and regulatory compliance exposures.
Dynamic Infrastructure Research Examples
Leveraging Blue Gene for large scale simulation
in the drug discovery process.
Smart Work Research Example
Building governance and maintenance tools to
support benefit configuration, research, and
correction processes.
Protecting the privacy of biometric data by
creating an anonymous biometrics recognition
system that scales to large populations.
New Intelligence Research Example
© 2010 IBM Corporation
At the center of smarter life sciencesis an increasingly more networked operation focused on the end patient.
COLLABORATING with other biophamra, academia
SHARING patient insights
UNDERSTANDING
fundamental of the
disease
INTEGRATING
all relevant data both
internally and externally
CONVERGING across industries
MONITORING and responding
to signals
MEASURING your progress
and plan
IMPROVING operations internally
COMPLYING with regulations
The result is also a safe, effective and valued treatment
solution targeted at the patient.
IMPROVED PATIENT INSIGHTS
REDUCED RISK FROM COUNTERFEITS
BETTER COMPLIANCE WITH TREATMENT
MORE INNOVATIVE DISCOVERY & DEVELOPMENT
© 2010 IBM Corporation
The imperative for life sciences today is clear.
ENGAGE
Interconnect researchers
from academic, industry and
regulators to bolster product
pipelines
Bridge internal silos with
better collaboration tools and
infrastructures
Build an integrated network
of manufacturing, and
distribution partners
OPERATE EFFECTIVELY
Optimize core systems and
infrastructure to reduce costs
and to more flexibly service
new business demands
Use technology to
communicate, share information
and assist in decision-support
Employ a fact-based,
quantitative risk management
approach in the supply chain
and by building intelligence into
products and packaging
INNOVATE
Develop strategies in
support of advanced
therapies and technologies,
such as gene and cell
therapies and
nanotechnology
Fuel drug discovery by
investing in innovative
decision-making
approaches
Maximize development with
the integration of modeling
and simulation into new
clinical trial programs
Use social networking to
connect globally to gather
insights to fuel innovation
© 2010 IBM Corporation
IBM’s solution strategy is aligned with the needs of all stakeholders of the life sciences companies.
LIFE SCIENCES SYSTEMS ARE FOCUSED ON… IBM IS INVESTING IN…
Streamline and transform
Collaborate and empower
Innovate and thrive Systems biology
Nanotechnology
Smarter Analytics & Information Agenda
Clinical decision support systems
Customer segmentation / e-detailing
Business process modeling, analytics and performance
management
Life Sciences Hub
Biopartnering strategy
Interoperability
Medical home: Patient-centered collaborative care
Patient portals
Collaborative platforms & tools
Risk Modeling
Universal Data Model/Warehouse
The New Pharma Commercial Model
Marketing and Sales
Regulatory Compliance
Pharmacoviligence
Content Management
Pharma Track and Trace
© 2010 IBM Corporation
Let’s work together to drive
real progress in our world.
We’ve only just begun to uncover what is possible on a smarter planet.
The world will continue to become smaller, flatter
and smarter. We are moving into the age of the
globally integrated and intelligent economy, society
and planet.
To thrive in a smarter planet, life sciences
organizations need to transform so they are more
streamlined internally and collaborating effectively
externally to deliver more innovative products.
There’s no better time to start building a smarter life
sciences industry to provide more patient-centric
treatment for society.
© 2010 IBM Corporation
Trademarks and notes
IBM Corporation 2009
IBM, the IBM logo and ibm.com are registered trademarks, and other company, product or
service names may be trademarks or service marks of International Business Machines
Corporation in the United States, other countries, or both. A current list of IBM trademarks is
available on the Web at ―Copyright and trademark information‖ at
www.ibm.com/legal/copytrade.shtml
Adobe, the Adobe logo, PostScript, the PostScript logo, Cell Broadband Engine, Intel, the
Intel logo, Intel Inside, the Intel Inside logo, Intel Centrino, the Intel Centrino logo, Celeron,
Intel Xeon, Intel SpeedStep, Itanium, IT Infrastructure Library, ITIL, Java and all Java-based
trademarks, Linux, Microsoft, Windows, Windows NT, the Windows logo, and UNIX are
trademarks or service marks of others as described under ―Special attributions‖ at:
http://www.ibm.com/legal/copytrade.shtml#section-special
Other company, product and service names may be trademarks or service marks of others.
References in this publication to IBM products or services do not imply that IBM intends to
make them available in all countries in which IBM operates.